Chemotherapy for Non-Melanoma Skin Cancer

 

Medication that kills cancer cells can be applied in a lotion or cream that is applied directly to the skin. This is called topical chemotherapy. This treatment may be chosen when the area affected by cancer is very large. Topical chemotherapy may produce side effects that include redness, swelling, itching, and burning. The drugs most often used for topical chemotherapy of non-melanoma skin cancer include the following:

  • Aldara® (imiquimod) is used topically to treat various types of skin cancer. It works by activating certain cells of the body’s immune system to attack and destroy cancer cells.
  • Efudex® and Fluoroplex® (5-fluorouracil, or 5-FU) are topical formulations of a commonly used anticancer drug. It works by disrupting the growth of cancer cells.
  • Alpha-interferon can be injected directly into cancerous lesions, causing them to regress. This drug works by activating the body’s immune system to destroy the cancer cells.

In advanced cases—most often in advanced squamous cell carcinoma—chemotherapy may consist of medication taken intravenously (by vein) (IV). Intravenous chemotherapy may cause nausea and vomiting, fatigue, hair loss, a low blood count, and other symptoms. These side effects usually disappear after treatment. The drugs used for intravenous chemotherapy of advanced non-melanoma skin cancer include the following: 

  • Platinol® (cisplatin) is a commonly used cancer drug that may be used alone or combined with doxorubicin or 5-fluorouracil to treat metastatic cases of non-melanoma skin cancer.
  • Adriamycin® (doxorubicin) is one of a family of anti-cancer drugs that work by stopping cancer cells’ ability to multiply and grow. Doxorubicin may be combined with cisplatin in cases of advanced non-melanoma skin cancer.
  • 5-Fluorouracil is a commonly used anticancer drug administered in IV form. It may be used in combination with cisplatin.
  • Mutamycin® (mitomycin) is used to treat squamous cell carcinoma of the head and neck, lungs, and cervix.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on February 21, 2008 .
Latest Cancer News
HPV infection rates similar in men and women

October 10, 2008 — NEW YORK (Reuters Health) - Although men are at high risk of acquiring human papillomavirus (HPV) infections, most last no more than a year, about the same time this sexually transmitted disease persists in women, researchers report in The Journal of Infectious Diseases.

Cancer common after liver transplantation

October 10, 2008 — NEW YORK (Reuters Health) - People who undergo liver transplantation, particularly children, are at increased risk for developing cancer, Finnish researchers report in the journal Liver Transplantation.

Lung cancer in non-smokers a separate disease

October 10, 2008 — NEW YORK (Reuters Health) - Japanese investigators say that survival rates are better for patients with non-small cell lung cancer (NSCLC) who never smoked than in NSCLC patients with a history of smoking. Other disease characteristics are different as well between the two populations.

Select news items provided by Reuters Health